GFCAS12
Live / Registered — Registered (as of 11 May 2021)
What this means for you
Registered since 11 May 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88862249
- Registration number
- 6344786
- Mark type
- Stylized text
- Filed
- 07 Apr 2020
- Published for opposition
- 23 Feb 2021
- Registered
- 11 May 2021
- Attorney of record
- Jun-Hwa Jeong
Goods and services
- Class 005 — Pharmaceuticals: Veterinary diagnostic reagents for use in veterinary genetic testing; Diagnostic preparations for veterinary purposes; Enzymes for medical purposes for genome editing-based therapy; Genome editing-based treatment preparations in the nature of preparations for detecting mutation in genes for medical purposes; Protein arrays for medical diagnostic purposes; Biological preparations for the treatment of cancers, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, diabetes, multiple sclerosis, heart attack, systemic lupus erythematous, age-related macular degeneration, diabetic retinopathy, prevention of pneumonia, anemia, chronic migraine, hepatitis B, hemophilia, respiratory syncytial virus (RSV) prophylaxis, HPV prevention, varicella virus vaccine, growth hormone deficiency, osteoporosis, allergic asthma, chronic idiopathic urticaria, infertility, prevention of meningococcal disease, cystic fibrosis, paroxysmal nocturnal hemoglobinuria, autoimmune diseases infectious diseases for medical or veterinary purposes; Cultures of microorganisms for medical purposes; Cells for medical purposes; Reagents for use in medical genetic testing; Stem cells for medical purposes; Diagnostic preparations for medical purposes; Medicinal protein in the nature of protein arrays for medical diagnostic purposes; Medicinal enzymes; Medicines for human purposes and medicines for animals in the nature of medicines for cancers, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, diabetes, multiple sclerosis, heart attack, systemic lupus erythematous, age-related macular degeneration, diabetic retinopathy, prevention of pneumonia, anemia, chronic migraine, hepatitis B, hemophilia, respiratory syncytial virus (RSV) prophylaxis, HPV prevention, varicella virus vaccine, growth hormone deficiency, osteoporosis, allergic asthma, chronic idiopathic urticaria, infertility, prevention of meningococcal disease, cystic fibrosis, paroxysmal nocturnal hemoglobinuria, autoimmune diseases, infectious diseases; Surgical implants grown from stem cells in the nature of surgical implants comprised of living tissue; Pharmaceutical preparations for genome editing-based therapy of rare inherited disorders; Ferments for medical or veterinary use; Preparations for detecting mutation in genes for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Enzymes for medical purposes
Owner
- G+FLAS Life Sciences, Inc., Seoul, KR
- G+FLAS Life Sciences, Inc., Seoul, KR
- G+FLAS Life Sciences, Inc., Seoul, KR
Prosecution history
- 11 May 2021 — REGISTERED-PRINCIPAL REGISTER
- 23 Feb 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 Feb 2021 — PUBLISHED FOR OPPOSITION
- 03 Feb 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 16 Jan 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 Dec 2020 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 28 Dec 2020 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 28 Dec 2020 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 02 Jul 2020 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 02 Jul 2020 — NON-FINAL ACTION E-MAILED
- 02 Jul 2020 — NON-FINAL ACTION WRITTEN
- 25 Jun 2020 — ASSIGNED TO EXAMINER
- 13 May 2020 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 13 May 2020 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 13 May 2020 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED